Literature DB >> 7987867

Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes.

G Stuhler1, P Walden.   

Abstract

Immunotherapy of cancer could be possible in cases in which competent effector T cells can be induced. Such an approach depends on expression of tumour-specific antigens by the tumour cells and on the availability of sufficient costimulatory support for activation of cytotoxic T lymphocytes. Here, a strategy for helper T cell recruitment for induction of tumour-specific cytotoxic immune responses is presented. Allogenic MHC class II molecules were introduced into tumour cells by cell fusion. These hybrid cells, when injected into mice, induced rejection of an established tumour. The contribution of CD4-expressing helper T cells in the induction phase and of CD8-expressing T cells in the effector phase of the immune response was demonstrated. The approach described could be applicable to cases in which a suitable tumour antigen is present but not identified; it employs regulatory interactions that govern physiological immune responses and is designed to be minimally invasive.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987867     DOI: 10.1007/BF01519989

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

Review 1.  Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.

Authors:  C J Melief
Journal:  Adv Cancer Res       Date:  1992       Impact factor: 6.242

Review 2.  Toward a genetic analysis of tumor rejection antigens.

Authors:  T Boon
Journal:  Adv Cancer Res       Date:  1992       Impact factor: 6.242

Review 3.  Cytokine gene transfer in tumor cells as an approach to antitumor therapy.

Authors:  M P Colombo; S Mattei; G Parmiani
Journal:  Int J Clin Lab Res       Date:  1992

Review 4.  Problems in the physiology of class I and class II MHC molecules, and of CD45.

Authors:  A G Fisher; L K Goff; L Lightstone; J Marvel; N A Mitchison; G Poirier; H Stauss; R Zamoyska
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1989

5.  Establishment and characterization of BALB/c lymphoma lines with B cell properties.

Authors:  K J Kim; C Kanellopoulos-Langevin; R M Merwin; D H Sachs; R Asofsky
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

6.  Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.

Authors:  S Yasumura; H Hirabayashi; D R Schwartz; J F Toso; J T Johnson; R B Herberman; T L Whiteside
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

7.  Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells.

Authors:  Y Guo; M Wu; H Chen; X Wang; G Liu; G Li; J Ma; M S Sy
Journal:  Science       Date:  1994-01-28       Impact factor: 47.728

Review 8.  Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Authors:  R A Maas; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 9.  T cell recognition of human tumors: implications for molecular immunotherapy of cancer.

Authors:  C G Ioannides; T L Whiteside
Journal:  Clin Immunol Immunopathol       Date:  1993-02

10.  Studies in antibody response of mice to tumour inoculation.

Authors:  P A GORER
Journal:  Br J Cancer       Date:  1950-12       Impact factor: 7.640

View more
  5 in total

Review 1.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

2.  Antigen organization regulates cluster formation and induction of cytotoxic T lymphocytes by helper T cell subsets.

Authors:  G Stuhler; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  Cell-cell electrofusion: optimization of electric field amplitude and hypotonic treatment for mouse melanoma (B16-F1) and Chinese Hamster ovary (CHO) cells.

Authors:  Marko Usaj; Katja Trontelj; Damijan Miklavcic; Masa Kanduser
Journal:  J Membr Biol       Date:  2010-07-14       Impact factor: 1.843

4.  Hybrid-cell vaccines for cancer immune therapy.

Authors:  Uwe Trefzer; Peter Walden
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 5.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.